Effects of Remote Ischemic Preconditioning on Decreasing Troponin Release in Patients Not Taking Sulfonylureas After Cardiac Surgery - A Meta-Analysis

ABSTRACT Introduction: Remote ischemic preconditioning (RIPC) is a new noninvasive myocardial protection strategy that uses blood pressure cuf inflation to simulate transient non-fatal ischemia to protect the myocardium and reduce ischemia-reperfusion injury. Sulfonylureas may mask the effects of RIPC due to their cardioprotec-tive effect. This meta-analysis aimed to evaluate whether RIPC, in the absence of sulfonylureas, reduces troponin release in patients undergoing cardiac surgery. Methods: We conducted a meta-analysis of randomized controlled clinical trials to determine whether RIPC can reduce postoperative troponin release in cardiac surgery patients undergoing cardiopulmonary bypass without treatment with sulfonylureas. The data were normalized to equivalent units prior to the analysis. A random-effects model was used to provide more conservative estimate of the effects in the presence of known or unknown heterogeneity. Results: Six studies with a total of 570 participants were included. The analysis showed that troponin release was lower in the RIPC group than in the control group at six hours (test of standardized mean differences = 0, Z=3.64, P<0.001) and 48 hours (Z=2.72, P=0.007) postoperatively. When the mean of cross-clamping time was > 60 minutes, RIPC reduced troponin release at six hours (Z=2.84, P=0.005), 24 hours (Z=2.64, P=0.008), and 48 hours (Z=2.87, P=0.004) postoperatively. Conclusion: In cardiac surgery patients who are not taking sulfonylureas, RIPC can reduce troponin release at six and 48 hours postoperatively; hence, RIPC may serve significant benefits in certain cardiac surgery patients.

Establishment of Mathematical Models for Skeletal Age Determination of Extremitas Sternalis of Clavicle in Shanxi Adolescents / 法医学杂志

Objective To develop mathematical models for skeletal age determination with multiple statistic method based on the correlation between age and the growth of the epiphysis of extremitas sternalis of clavicle in Shanxi adolescents. Methods The 562 Shanxi sternoclavicular joint samples （454 cases of modelling, 108 cases of external verification） were scanned by the thin-section computed tomography. After volume rendering was obtained, indicators such as area of epiphysis, area of metaphysis, longest diameter of epiphysis and longest diameter of metaphysis of both extremitas sternalis of clavicle were collected. Indicators such as the ratio of area of epiphysis to area of metaphysis, and the ratio of longest diameter of epiphysis to longest diameter of metaphysis of both sides were calculated. Then multiple linear regression and random forest discriminant models were used to build mathematical models for age determination of adolescents. Results The obtained indicators exhibited a strong correlation with age （r>0.85）. The multiple linear regression model for males and females （all 4 indicators entering the model） based on the ratio of longest diameter of epiphysis to longest diameter of metaphysis and the ratio of area of epiphysis to area of metaphysis had an internal validation accuracy rate （±1.0 year） of over 92% and 108 cases had an external validation accuracy rate of over 70% （±1.0 year）. The out of bag error rates of random forest discriminant models were less than 2% for people over 18.0 years old （≥18.0 years old） and under 18.0 years old. The external validation accuracy rates of the 108 cases were over 80%. Conclusion The regression and discriminant models established in this study have certain reliability and accuracy and can be used in age determination of Shanxi adolescents.

DEC1: a potential biomarker of malignant transformation in oral leukoplakia

Abstract The purpose of this study was to analyze the differential expression of DEC1 in oral normal mucosa (NM), oral leukoplakia (OLK) and oral squamous cell carcinoma (OSCC). Surgically excised specimens from patients with OLK (n = 47), OSCC (n = 30) and oral normal mucosa (n=11) were immunostained for DEC1. The expression of DEC1 protein was evaluated, and its association with the clinicopathological features was analyzed. The expression of DEC1 in NM, OLK and OSCC tissues increased in turn, and significant differences were observed among the groups (P < 0.0001). In terms of the association between DEC1 expression and epithelial dysplasia, DEC1 expression was lower in hyperkeratosis without dysplasia (H-OLK) than in OLK with moderate to severe dysplasia (S-OLK), and these differences were significant (p < 0.05). The expression of DEC1 in OSCC with OLK was significantly higher than that in OSCC without OLK (p < 0.01). Therefore, DEC1 could be a potential biomarker of malignant transformation in the carcinogenesis of OSCC, which may provide a new research direction for the transformation of oral potentially malignant disorders (OPMDs) into OSCC.

Mucoepidermoid carcinoma arising in Warthin’s tumor of the upper lip: a case report and review / 口腔疾病防治

Objective @#To provide a reference for the diagnosis and treatment of mucoepidermoid carcinoma arising in Warthin’s tumor of the lip by investigating the diagnosis, treatment and prognosis of the disease.@*Methods @# A case of mucoepidermoid carcinoma arising in Warthin’s tumor of lip was reported, including the clinical manifestation, treatment, pathological characteristics and prognosis. The related literature was also reviewed and analyzed.@*Results@# A painless mass on the left lip lasting more than one month was found. Resection of the left lip was performed. Pathological examination showed that the tumor was a hybridoma composed of mucoepidermoid carcinoma and Warthin’s tumor. There was no recurrence or distant metastasis after 34 months. To date, this type of disease has been rarely reported. After thorough resection, the prognosis and survival rate are promising in most cases, with no recurrence or metastasis.@*Conclusion@#Mucoepidermoid carcinoma in Warthin’s tumor of the lip is rare. Clinical manifestations, imaging features and histological examination are useful when diagnosing the disease. Thorough resection will reduce the risk of disease recurrence.

Antitumor activity and acute toxicity of total saponins from Paris forrestii / 药物评价研究

Objective To detect the antitumor activity of total saponins form Parisforrestii (PCT3) in vitro and in vivo and its acute toxicity by disposable ig administration.Methods The inhibitory effect of PCT3 on proliferation of human colorectal cancer cells (HCT-116) and human gastric cancer cells (SGC-7901) was detected by modified MTT assay,and the half inhibition concentration (IC50) was calculated.Acute toxicity test of PCT3 at doses of 1 646,2 352,3 360 and 4 800 mg/kg was performed by ig administration in mice.Mouse model of hepatocellular carcinoma (H22) was established with sc injection,and the mice were respectively ip given cisplatin 2 mg/kg (positive control),normal saline (negative control),ig given 0.5％ CMC-Na (solvent control),30,90 and 270 mg/kg PCT3 continuously for 9 d,and the inhibitory rate of tumor,body weight,liver,spleen,kidney and thymus coefficients were detected.Results PCT3 had significant inhibitory effect on the proliferation of HCT-116 and SGC-7901 cells,with IC50 values of 7.6 and 5.9 μg/mL,respectively.PCT3 induced animal diarrhea and activity inhibition in mice,the half lethal dose (LD50) was 1985.5 mg/kg.Compared with solvent control group,PCT3 had no significant effect on body weight of mice;270 mg/kg PCT3 had a significant inhibitory effect on H22 tumor mass (P ＜ 0.05),the inhibitory rate was 26.8％;There was no significant effect on the organ coefficient;compared with negative control group,cisplatin significantly inhibited the tumor growth and body weight (P ＜ 0.01),the inhibitory rates were 81.4％ and 37.4％ respectively;The liver,spleen and thymus coefficients were also significantly inhibited (P ＜ 0.05,0.01).Conclusion The tumor inhibitory rate of cisplatin is significantly higher than that of PCT3,but it also significantly inhibits mice body weight and liver,spleen,thymus coefficients.PCT3 shows obvious antitumor activity in vitro and in vivo,and the toxicity is not remarkable.It could be a potential antitumor agent in the future.

Antitumor activity and acute toxicity of total saponins from Paris forrestii / 药物评价研究

Objective To detect the antitumor activity of total saponins form Parisforrestii (PCT3) in vitro and in vivo and its acute toxicity by disposable ig administration.Methods The inhibitory effect of PCT3 on proliferation of human colorectal cancer cells (HCT-116) and human gastric cancer cells (SGC-7901) was detected by modified MTT assay,and the half inhibition concentration (IC50) was calculated.Acute toxicity test of PCT3 at doses of 1 646,2 352,3 360 and 4 800 mg/kg was performed by ig administration in mice.Mouse model of hepatocellular carcinoma (H22) was established with sc injection,and the mice were respectively ip given cisplatin 2 mg/kg (positive control),normal saline (negative control),ig given 0.5％ CMC-Na (solvent control),30,90 and 270 mg/kg PCT3 continuously for 9 d,and the inhibitory rate of tumor,body weight,liver,spleen,kidney and thymus coefficients were detected.Results PCT3 had significant inhibitory effect on the proliferation of HCT-116 and SGC-7901 cells,with IC50 values of 7.6 and 5.9 μg/mL,respectively.PCT3 induced animal diarrhea and activity inhibition in mice,the half lethal dose (LD50) was 1985.5 mg/kg.Compared with solvent control group,PCT3 had no significant effect on body weight of mice;270 mg/kg PCT3 had a significant inhibitory effect on H22 tumor mass (P ＜ 0.05),the inhibitory rate was 26.8％;There was no significant effect on the organ coefficient;compared with negative control group,cisplatin significantly inhibited the tumor growth and body weight (P ＜ 0.01),the inhibitory rates were 81.4％ and 37.4％ respectively;The liver,spleen and thymus coefficients were also significantly inhibited (P ＜ 0.05,0.01).Conclusion The tumor inhibitory rate of cisplatin is significantly higher than that of PCT3,but it also significantly inhibits mice body weight and liver,spleen,thymus coefficients.PCT3 shows obvious antitumor activity in vitro and in vivo,and the toxicity is not remarkable.It could be a potential antitumor agent in the future.

Corticotropin-releasing Factor Changes the Phenotype and Function of Dendritic Cells in Mouse Mesenteric Lymph Nodes

BACKGROUND/AIMS: Dendritic cells (DCs) are a significant contributor to the pathology of numerous chronic inflammatory autoimmune disorders; however, the effects of Corticotropin-releasing factor (CRF) on intestinal DCs are poorly understood. In this study, we investigated the role of CRF in alterations of intestinal dendritic cell phenotype and function. METHODS: Mouse mesenteric lymph node dendritic cells (MLNDCs) were obtained using magnetic bead sorting. Surface expression of CRF receptor type 1 (CRF-R1) and CRF-R2 was determined by double-labeling immunofluorescence and quantitative polymerase chain reaction (qPCR) and MLNDCs were subsequently exposed to CRF in the presence or absence of CRF-R1 and CRF-R2 antagonists. Expression of surface molecules (MHC-I and MHC-II) and co-stimulatory molecules (CD80 and CD86) was determined by flow cytometric and western blot analyses, and the T cell stimulatory capacity of MLNDCs was evaluated by mixed lymphocyte reaction. RESULTS: Immunofluorescent staining and quatitative polymerase chain reaction indicated that both the CRF receptors (CRF-R1 and CRF-2) are expressed on the surface of MLNDCs. Exposure to CRF increased the expression of MHC-II on MLNDCs as well as their capacity to stimulate T cell proliferation. MLNDCs treated with CRF-R1 antagonist exhibited a phenotype characterized by a less activated state and reduced surface expression of MHC-II, and consequently showed reduced capacity to stimulate T cells. In contrast, treatment of MLNDCs with CRF-R2 antagonist yielded an opposite result. CONCLUSIONS: CRF can alter the phenotype and function of intestinal DCs through direct action on CRF-R1 and CRF-R2, and activation of the CRF-R1 and CRF-R2 pathways yields opposing outcomes.